A Phase 3 interventional study of Reduced Dose Alteplase and Standard Dose Alteplase in Complicated Parapneumonic Effusion, Empyema, Pleural and Pleural Infection, sponsored by Vanderbilt University Medical Center. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Vanderbilt University Medical Center · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Pleural infections are common and associated with significant illness and healthcare burden, often requiring hospitalization, antibiotics, chest tube drainage, and sometimes surgery. Intrapleural enzyme therapy (IET), which involves administering two medications, alteplase (10 mg) and DNase (5md), directly into the pleural space through a chest tube, has been shown to improve drainage of infected fluid, reduce the need for surgical referral, and shorten hospital stays based in a clinical trial. Alteplase dosing has ever been determined through formal dose-finding studies. It remains unclear whether lower doses may provide similar benefits.
The DREAMS trial aims to determine whether a lower dose of alteplase can achieve comparable treatment outcomes, while potentially reducing medication-related risks.
Participants will:
Pleural infections an incidence of over 80,000 cases per year in the US and U.K., causing significant burden to healthcare systems. Pleural infection causes fibrin deposition and septation formation within the pleural space that impedes chest tube drainage and has resulted in the investigation of intrapleural treatments to avoid the need for more invasive procedural management. British Thoracic Society (BTS) 2023 Guidelines recommend treatment of pleural infections with antimicrobials along with drainage of the infected pleural space via tube thoracostomy drainage, with the use of intrapleural enzyme therapy (IET), when initial chest tube drainage ceases.
The Multicenter Intrapleural Sepsis Trial (MIST2 Trial), demonstrated that intrapleural alteplase 10mg in combination with DNase 5mg administered twice daily for six doses improves drainage of fluid as measured by chest X-ray (CXR), reduce the need for surgical referral and hospital length of stay compared with placebo, and has established IET as standard of care for the treatment of pleural infections.
Alteplase can lead to pain and potential pleural hemorrhage at "standard," 10mg dosage. Whether a reduced alteplase dose could retain efficacy, reduce potential risks such as intrapleural hemorrhage and cost (75% of which is the cost of alteplase) compared with standard dosing, is unknown.
Observational data supporting that a reduced dose alteplase retains similar efficacy compared with standard of care dosing and had led to adoption by clinicians for those deemed at heightened bleeding risk without formal clinical trial guidance. As a result of these observational studies, the 2023 BTS pleural disease guidelines notes a reduced dose alteplase may be considered in those with a potentially higher bleeding risk. Ultimately, there have been no randomized clinical trials assessing the efficacy of reduced dose alteplase.
The DREAMS trial is a randomized controlled trial evaluating the non-inferiority of a dose reduced alteplase compared with standard of care dosing in the management of pleural infection.
33 studies on the registry are indexed under Empyema, Pleural; 11 are open to participants now.
This study's planned enrollment of 248 is above the median of 77 across 26 interventional studies indexed under Empyema, Pleural.
Browse Empyema, Pleural studies →Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alteplase 4mg with 5mg DNase twice daily for six doses
Drug: Reduced Dose Alteplase
Alteplase 10mg with 5mg DNase twice daily for six doses
Drug: Standard Dose Alteplase
Reduced dose alteplase (4mg) with 5mg DNase administered intrapleurally, twice daily for six doses
Also known as: Tissue Plasminogen Activator, Intrapleural Alteplase, Intrapleural Enzyme Therapy
Alteplase 10mg with 5mg DNase administered twice daily for six doses
Also known as: Tissue Plasminogen Activator, Intrapleural enzyme therapy, Intrapleural alteplase
Treatment Success
Proportion of patients achieving treatment success (absence of ongoing pleural infection despite IET regimen initiation, requiring alternate or additional treatment or resulting in death) at 60 days post IET initiation
Time frame: From enrollment to standard treatment follow-up within 60 days following the first dose of intrapleural enzyme therapy
No study locations are listed for this record.
Plan to share: No — Deidentified data will be shared with other researchers
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jun 2028, 17 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanderbilt University Medical Center →